Skip to main content

Table 1 Active amyloid-beta immunotherapies in development

From: Active immunotherapy options for Alzheimer’s disease

Compound Sponsor Epitope/carrier/adjuvant Route of administration Phase of development Population
CAD106 Novartis (Basel, Switzerland) 1–6/bacteriophage Qβ coat protein i.m./s.c. 2 Mild-to-moderate AD
ACC-001 (vanutide cridificar) Pfizer (New York, USA)/Janssen Research & Development, LLC (Raritan and Titusville, NJ, USA) 1–7/nontoxic diphtheria toxin (CRM197)/Qs21 adjuvant i.m. 2 Mild-to-moderate AD, early AD
AD02 AFFiRiS (Vienna, Austria)/GlaxoSmithKline (Brentford, UK) 1–6 mimetic/keyhole limpet hemocyanin/aluminum adjuvant s.c. 2 Mild-to-moderate AD, early AD
ACI-24 AC Immune (Lausanne, Switzerland) Tetra-palmitoylated Aβ1 15/reconstituted in liposome s.c. 1/2 Mild-to-moderate AD
V950 Merck & Co. (Whitehouse Station, NJ, USA) Multivalent Aβ peptide/ISCOMATRIX™ adjuvant i.m. 1 (discontinued) Mild-to-moderate AD
UB-311 United Biochemical, Inc. (Hauppauge, NY, USA) Two UBITh® synthetic peptides coupled to Aβ1–14 peptide/CpG oligonucleotide i.m. 2 Mild-to-moderate AD
Lu AF20513 Lundbeck A/S (Valby, Denmark) 1 12 peptide replaced with two foreign T-helper epitopes from tetanus toxoid N/A Preclinical Early AD
  1. , amyloid-beta protein; AD, Alzheimer’s disease; i.m., intramuscular; s.c., subcutaneous.